ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia

Nature Communications
Jean-Baptiste MicolOmar Abdel-Wahab

Abstract

Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a haploinsufficient tumour suppressor. While Asxl2 was required for normal haematopoietic stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2 target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was associated with increased chromatin accessibility at putative enhancers of key leukemogenic loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO.

References

Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·T MiyamotoK Akashi
Dec 13, 2000·Molecular and Cellular Biology·U ThorsteinsdottirG Sauvageau
Mar 20, 2004·Developmental Cell·Patricia ErnstStanley J Korsmeyer
Oct 25, 2007·Nature Reviews. Cancer·Andrei V Krivtsov, Scott A Armstrong
Sep 19, 2008·Genome Biology·Yong ZhangX Shirley Liu
Nov 4, 2008·Cancer Cell·Andrei V KrivtsovScott A Armstrong
Apr 25, 2009·British Journal of Haematology·Véronique Gelsi-BoyerDaniel Birnbaum
Feb 5, 2010·Blood·Christian BachRobert K Slany
Nov 26, 2010·Proceedings of the National Academy of Sciences of the United States of America·Menno P CreyghtonRudolf Jaenisch
Dec 17, 2010·Nature·Alvaro Rada-IglesiasJoanna Wysocka
May 13, 2011·Nature·Apostolos KlinakisIannis Aifantis
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholArnold Ganser
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Sep 14, 2011·Methods in Molecular Biology·Henriette O'GeenPeggy J Farnham
Nov 8, 2011·Haematologica·Marta PratcoronaPeter J M Valk
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Aug 11, 2012·Science·Anwesha DeyVishva M Dixit
May 22, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Raphaël ItzyksonEric Solary
Nov 13, 2013·The Journal of Experimental Medicine·Omar Abdel-WahabRoss L Levine
Nov 21, 2013·Blood·Jiapeng WangFeng-Chun Yang
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Nov 27, 2014·The New England Journal of Medicine·Giulio GenoveseSteven A McCarroll

❮ Previous
Next ❯

Citations

Sep 19, 2018·The Journal of Clinical Investigation·Peng ZhangFeng-Chun Yang
Aug 24, 2018·F1000Research·Justin Watts, Stephen Nimer
Mar 31, 2019·Cellular and Molecular Life Sciences : CMLS·Shuhei AsadaToshio Kitamura
Apr 13, 2018·The Journal of Experimental Medicine·Reina NagaseToshio Kitamura
Dec 30, 2018·Proceedings of the National Academy of Sciences of the United States of America·Na LiuXiao-Jian Sun
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Andrew KuykendallJohn S Welch
Oct 23, 2019·Annals of Hematology·Xiang ZhangWenjuan Yu
Sep 26, 2019·Frontiers in Oncology·Bettina Wingelhofer, Tim C P Somervaille
Jul 17, 2020·Science Advances·Cecilia Pessoa RodriguesAsifa Akhtar
Oct 28, 2020·International Journal of Molecular Sciences·Cameron J ReddingtonPeter D Mace
Sep 17, 2020·Science Advances·Cecilia Pessoa RodriguesAsifa Akhtar
Mar 23, 2021·American Journal of Medical Genetics. Part a·Vishnu Anand CuddapahEric D Marsh
Apr 29, 2021·Expert Opinion on Therapeutic Targets·Fanny GonzalesMeyling H Cheok
Apr 30, 2021·Frontiers in Immunology·Yun Hsiao LinAnastasia Nijnik
May 1, 2021·Leukemia & Lymphoma·Jacqueline WallwitzDagmar Stoiber
Sep 19, 2021·Journal of Molecular Biology·Abigail E BurgessPeter D Mace

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE84365

Methods Mentioned

BETA
PCR
immunoprecipitation
ChIP-seq
co-immunoprecipitation
RNA-seq
transfection
flow cytometry
FACS
ChIP
electrophoresis

Clinical Trials Mentioned

NCT00428558

Software Mentioned

Basepair
Cufflinks
ImageJ
bigwig
Picard

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.